AI ScreeningAI ChatPricing
  1. JP-listed companies
  2. SHIN NIPPON BIOMEDICAL LABORATORIES, LTD.
  3. Financials
  4. Total cash & short-term investments

SHIN NIPPON BIOMEDICAL LABORATORIES, LTD.【JP:2395】

Market cap
¥64.4B
P/E ratio
18.1x
Provides drug development testing services to pharmaceutical companies and operates innovative intranasal drug delivery technology through spinout companies.
SummaryFinancialsDividendsHistoryOwnershipWorkforce
Period EndTotal cash & short-term investments (Million JPY)YoY (%)
Mar 31, 202512,032+13.39%
Mar 31, 202410,611+0.74%
Mar 31, 202310,533+50.54%
Mar 31, 20226,997-3.97%
Mar 31, 20217,287+38.80%
Mar 31, 20205,250+2.11%
Mar 31, 20195,142-3.22%
Mar 31, 20185,313-28.66%
Mar 31, 20177,447+50.68%
Mar 31, 20164,942-32.08%
Mar 31, 20157,276

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)